Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 18 years * Angioid streaks * Subfoveal CNV of recent onset with the following characteristics * Absence of subfoveal fibrosis * Fibrosis less than 25% of the lesion * Presence of blood, subretinal fluid, and/or lipid * New onset symptoms within 12 weeks * Visual acuity 20/40 to 20/800 on an ETDRS chart Exclusion Criteria: * Prior treatment of subfoveal CNV in the study eye * Age-related macular degeneration * Uncontrolled glaucoma * High myopia (\> -10.00 D spherical equivalent) * Prior retinal detachment * Media opacity preventing adequate view of the retina * Planned cataract surgery in the next 3 months * Current chemotherapy for cancer * Immunocompromised state * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial * History of any previous treatment for angioid streaks